Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W K Kelly

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
European Urology|December 17, 1998
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancerW K Kelly
Current Opinion in Oncology|May 1, 1994
Prostate cancer: how can a common disease be so controversial?W K Kelly, H I Scher
Current Oncology Reports|December 21, 2000
Chemotherapy for androgen- independent prostate cancer: myth or realityW K Kelly, S F Slovin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerH I Scher, W K Kelly
The Journal of Urology|March 1, 1993
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndromeW K Kelly, H I Scher
The Urologic Clinics of North America|May 1, 1997
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significanceW K Kelly, S Slovin, H I Scher
Journal of the National Cancer Institute|November 20, 1996
Clinical trials in relapsed prostate cancer: defining the targetH I Scher, M Mazumdar, W K Kelly
Urology|August 1, 1995
Hormone-refractory (D3) prostate cancer: refining the conceptH I Scher, G Steineck, W K Kelly
Seminars in Oncology|December 1, 1996
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancerW K Kelly, S Slovin, H I Scher
Seminars in Urologic Oncology|March 21, 1998
Immunological approaches for the treatment of prostate cancerS F Slovin, W K Kelly, H I Scher
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
European Urology|December 17, 1998
Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancerW K Kelly
Current Opinion in Oncology|May 1, 1994
Prostate cancer: how can a common disease be so controversial?W K Kelly, H I Scher
Current Oncology Reports|December 21, 2000
Chemotherapy for androgen- independent prostate cancer: myth or realityW K Kelly, S F Slovin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancerH I Scher, W K Kelly
The Journal of Urology|March 1, 1993
Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndromeW K Kelly, H I Scher
The Urologic Clinics of North America|May 1, 1997
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significanceW K Kelly, S Slovin, H I Scher
Journal of the National Cancer Institute|November 20, 1996
Clinical trials in relapsed prostate cancer: defining the targetH I Scher, M Mazumdar, W K Kelly
Urology|August 1, 1995
Hormone-refractory (D3) prostate cancer: refining the conceptH I Scher, G Steineck, W K Kelly
Seminars in Oncology|December 1, 1996
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancerW K Kelly, S Slovin, H I Scher
Seminars in Urologic Oncology|March 21, 1998
Immunological approaches for the treatment of prostate cancerS F Slovin, W K Kelly, H I Scher
Pageof 4